5,040.00
0.00
(0.00%)
At close: April 1 at 4:05:30 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
811,415,000
--
802,755,000
630,595,000
566,776,000
Cost of Revenue
254,427,000
--
342,291,000
281,322,000
248,006,000
Gross Profit
556,988,000
--
460,464,000
349,273,000
318,770,000
Operating Expense
336,419,000
--
308,473,000
213,759,000
205,010,000
Operating Income
220,569,000
--
151,991,000
135,514,000
113,760,000
Net Non Operating Interest Income Expense
43,221,000
--
-10,449,000
6,056,000
-999,000
Pretax Income
255,315,000
--
165,663,000
146,575,000
115,164,000
Tax Provision
24,902,000
--
-5,087,000
5,395,000
9,112,000
Net Income Common Stockholders
229,129,000
--
169,076,000
139,626,000
104,683,000
Diluted NI Available to Com Stockholders
229,129,000
--
169,076,000
139,626,000
104,683,000
Basic EPS
1.25k
860.00
907.00
751.00
563.00
Diluted EPS
1.25k
860.00
907.00
751.00
563.00
Basic Average Shares
183,118.02
184,769
186,333
186,008
185,971
Diluted Average Shares
183,118.02
184,769
186,333
186,008
185,971
Total Operating Income as Reported
138,113,000
--
153,555,000
135,832,000
115,089,000
Total Expenses
590,846,000
--
650,764,000
495,081,000
453,016,000
Net Income from Continuing & Discontinued Operation
229,129,000
--
169,076,000
139,626,000
104,683,000
Normalized Income
235,224,252.54
--
180,657,570
141,171,924.61
105,766,096
Interest Income
21,899,000
--
13,418,000
2,950,000
915,000
Interest Expense
14,424,000
--
8,030,000
663,000
631,000
Net Interest Income
43,221,000
--
-10,449,000
6,056,000
-999,000
EBIT
269,739,000
--
173,693,000
147,238,000
115,795,000
EBITDA
319,389,000
--
222,262,000
192,160,000
155,641,000
Reconciled Cost of Revenue
254,427,000
--
342,291,000
281,322,000
248,006,000
Reconciled Depreciation
49,650,000
--
48,569,000
44,922,000
39,846,000
Net Income from Continuing Operation Net Minority Interest
229,129,000
--
169,076,000
139,626,000
104,683,000
Total Unusual Items Excluding Goodwill
-6,754,000
--
-12,727,000
-1,605,000
-1,176,000
Total Unusual Items
-6,754,000
--
-12,727,000
-1,605,000
-1,176,000
Normalized EBITDA
326,143,000
--
234,989,000
193,765,000
156,817,000
Tax Rate for Calcs
0
--
0
0
0
Tax Effect of Unusual Items
-658,747.46
--
-1,145,430
-59,075.39
-92,904
12/31/2020 - 10/29/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
AWY0.F Percheron Therapeutics Ltd. R
0.0040
-11.11%
4547.T Kissei Pharmaceutical Co., Ltd.
3,540.00
-3.67%
D8Y0.DU Sandoz Group AG
34.20
+3.01%
MRK.DE Merck KGaA
115.30
+2.53%
SCYX SCYNEXIS, Inc.
0.8700
-0.71%
SIGA SIGA Technologies, Inc.
5.96
+0.59%
PRFX PainReform Ltd.
2.0800
-3.26%
CGC Canopy Growth Corporation
0.9400
+9.43%